April 5, 2017
MSD K.K. President Jannie Oosthuizen MSD Japan is looking to see the growth of its anti-PD-1 antibody Keytruda (pembrolizumab) in 2017 after the company saw its Japan sales dwindle 7.8% to 312 billion yen on an NHI price basis in...read more